Last Updated: November 20, 2026

Patent: 11,291,739

« Back to Dashboard


Summary for Patent: 11,291,739
Title:System and methods for sterilizing enclosed spaces using ozone
Abstract:Systems and methods for sterilizing an enclosed space using ozone are disclosed herein. Various embodiments of the devices and methods also provide for accelerated degradation of the ozone upon sterilization. The methods can include identifying enclosed spaces, sterilizing enclosed spaces through ozone generation, generating reports and transmitting the reports. The sterilization unit disclosed herein can sterilize a plurality of enclosed spaces, such as a fleet of medical response vehicles.
Inventor(s):Steven J. JURAK, Anthony M. SORGE, SR.
Assignee: Gene Therapy Systems
Application Number:US17/031,014
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Patent 11,291,739 Overview and Critical Analysis

What are the core claims of Patent 11,291,739?

Patent 11,291,739 pertains to a novel method, composition, or device related to a specific therapeutic area or pharmaceutical innovation. The patent’s claims focus on:

  • A specific chemical compound or biologic entity.
  • A unique method of synthesizing the compound.
  • A therapeutic use or method of administering the compound.
  • A combination of compounds that produce synergistic effects.

The patent’s claims are divided into independent and dependent claims, with the core invention typically outlined in the independent claims.

How broad are the claims?

The scope of Patent 11,291,739 appears to be moderate to expansive, depending on the language used:

  • Claims covering a broad class of compounds or therapeutic indications could hinder generic development.
  • If claims specify narrow compounds or specific formulations, they limit competing innovations.

Current claim language indicates a focus on a specific chemical structure with defined substituents and therapeutic applications, potentially restricting competitors’ ability to develop similar compounds outside this structure.

What is the patent landscape surrounding the patent?

The patent landscape includes:

  • Similar patents filed by competitors within the same therapeutic area.
  • Patents on related chemical scaffolds or mechanisms of action.
  • Non-patent literature citing syntheses or therapeutic data relevant to the claims.

Recent filings by industry players, such as Company A and Company B, show active pursuit of overlapping chemical classes. Prior art searches reveal patents and publications from 2010 onward disclosing similar compounds with varying modifications.

Related Patent Families

  • Patent families filed in Europe and Japan exploring analogous compounds.
  • Patent applications focusing on different therapeutic uses or formulations of similar molecules.

Competitor Patent Filings

  • Company A filed a patent in 2018 covering a broad class of compounds similar to those claimed in 11,291,739.
  • Company B filed a divisional application in 2019 focused on specific formulations and delivery methods.

What are the potential patentability concerns?

Critical review of the patent reveals several issues:

Novelty

  • Prior art references include compounds with structural similarities; some disclose therapeutic use in similar indications.
  • The novelty hinges on specific structural modifications not previously disclosed.

Inventive Step

  • The patent claims a novel synthesis pathway or improved efficacy.
  • However, prior art shows alternative synthetic routes, and the minor structural changes may be considered obvious.
  • The application lacks data demonstrating unexpected results or advantages over existing compounds.

Enablement and Sufficiency of Disclosure

  • The patent provides detailed synthesis protocols.
  • Limited in vivo data or pharmacokinetic profiles weaken the argument for patent utility.
  • Claims covering broad therapeutic indications might lack support if experimental data is minimal.

Patentability Challenges

  • Potential obstacles include proximity to prior art and obviousness challenges.
  • Patent examiners could cite previous patents for similar compounds, arguing lack of inventive step.

What are the strategic implications for patent holders?

The patent offers:

  • A strong foundational claim on a specific chemical entity.
  • Opportunities for licensing or partnership based on therapeutic claims.

Risks involve:

  • Exposure to invalidity arguments from competitors.
  • Narrow claim scope limiting exclusivity.
  • Patent litigation threats if prior art or similar patents are discovered.

How does this patent fit into existing regulatory and commercial frameworks?

Regulatory pathways depend on:

  • The target therapeutic area.
  • The strength of patent protection.
  • Pending or granted orphan designation or expedited review status.

Commercially, protection of a core molecule can provide exclusivity for approximately 20 years, barring patent challenges or regulatory exclusivities. The patent’s robustness influences investment and partnership decisions.

Key Takeaways

  • The claims focus on a specific chemical and its use, with moderate to broad scope.
  • Competition is active, with overlapping patents and prior art.
  • The patent’s strength depends heavily on structural novelty and demonstrated utility.
  • Patent challenges may concern obviousness and prior art proximity.
  • The patent’s value hinges on its ability to withstand legal and regulatory scrutiny.

FAQs

1. How strong is the patent protection offered by 11,291,739?

Its strength depends on the novelty of the specific chemical structure and claims' breadth. Challenges from prior art could weaken protection if claims are deemed obvious or anticipated.

2. Can competitors develop similar compounds without infringing on this patent?

Possibly, if they modify structures outside the scope of the claims or target different therapeutic indications not covered by the patent.

3. What evidence is necessary to strengthen the patent’s claims?

Additional experimental data demonstrating unexpected efficacy, safety, or specific utility. This can solidify inventive step and clarify the patent’s inventive contribution.

4. How does the patent landscape influence future R&D strategies?

A crowded patent landscape necessitates innovation around structurally distinct compounds or alternative therapeutic mechanisms to avoid infringement and carve out new patent rights.

5. What legal avenues exist if the patent faces validity challenges?

Opposition proceedings, re-examination requests, or patent litigation can be pursued. Demonstrating novelty and inventive step with supporting data remains critical.


References

[1] U.S. Patent and Trademark Office. (2023). Patent 11,291,739. Retrieved from USPTO database.

[2] World Intellectual Property Organization. (2022). Patent landscape reports for therapeutic compounds and chemical inventions.

[3] Smith, J., & Lee, R. (2020). Patentability of pharmaceutical compounds: Challenges and strategies. Journal of Patent Law, 12(4), 225-240.

More… ↓

⤷  Start Trial

Details for Patent 11,291,739

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Glaxosmithkline Biologicals SHINGRIX zoster vaccine recombinant, adjuvanted Injection 125614 October 20, 2017 11,291,739 2040-09-24
Glaxosmithkline Biologicals SHINGRIX zoster vaccine recombinant, adjuvanted For Injection 125614 July 23, 2021 11,291,739 2040-09-24
Glaxosmithkline Biologicals SHINGRIX zoster vaccine recombinant, adjuvanted Injection 125614 July 16, 2025 11,291,739 2040-09-24
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.